Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 25 versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 25 versus QDOLO.
FENTANYL-25 vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia by activating G-protein coupled opioid receptors in the CNS, leading to decreased neurotransmitter release and hyperpolarization of neurons.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
25 mcg/h transdermal patch applied every 72 hours; for opioid-tolerant patients only.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in healthy adults; prolonged to 3-12 hours in elderly, hepatic impairment, or critical illness; context: duration of action shorter due to redistribution.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal (75% as metabolites, <10% unchanged); Fecal (9%); Biliary (minor).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist